Editor in Chief Dr KK Aggarwal, Padma Shri Awardee                                                                               Dated:02 May,2020

Remdesivir: The Covid-19 drug helping patients recover faster

WASHINGTON: Remdesivir has been shown to speed up recovery times for patients with Covid-19 in a major US-led trial, becoming the first drug with proven benefit against the disease.
Here is what you need to know.
What is remdesivir?
Remdesivir is an experimental, broad spectrum antiviral made by US pharmaceutical Gilead Sciences that was first developed to treat Ebola, a viral hemorrhagic fever....read more


CMAAO Coronavirus Facts and Myth Buster 78

(With regular inputs from Dr Monica Vasudev)
Post lock down surveillance
A surveillance initiative was implemented in Shenzhen, China, to isolate and contact trace people suspected of having the COVID-19 coronavirus. This resulted in faster confirmation of new cases and reduced the window of time during which people were infectious in the community. This potentially decreased the number of new infections arising from each case, revealed a study of patients and contacts over 4 weeks (Lancet Infect Dis. 2020 Apr 27. doi: 10.1016/S1473-3099[20]30287-5).... read more


CMAAO Coronavirus Facts and Myth Buster 77

(With regular inputs from Dr Monica Vasudev)
Evidence on spironolactone safety, COVID-19 reassuring for acne patients
Concerns have been raised about potential risks with the use of spironolactone for acne during the COVID-19 pandemic on social media; however, spironolactone and other androgen blockers might actually protect against the virus, suggests a report published in the Journal of the American Academy of Dermatology.
The virus needs androgens to infect cells, and uses androgen-dependent transmembrane protease serine 2 to prime viral protein spikes to anchor onto ACE2 receptors. In the absence of this step, the virus is not able to enter the cells. Androgens are the only known activator in humans, so androgen blockers like spironolactone could possibly short-circuit the process,...read more


Facts about Soul and the Spirit

Energy is the raw material of the universe.
Information is the organization of energy into reproducible patterns.
Consciousness is living information and energy (living energized information).
Consciousness is, therefore, intelligence....read more


Video of The day

Sun Light, Heat, Humidity will Kill Corona Viruses


Health Sutras By Dr K K Aggarwal

Thermal screening is not the test for Covid 19


Medbytes

       


Healthcare News Monitor

Exclusive: Gilead says open to collaborate with govts, drug firms to make Remdesivir globally available
moneycontrol- Viswanath Pilla

Gilead Sciences, the US-drug maker said it is open to collaborate with governments, pharmaceutical companies, including from India, and is even considering proposals of patent-pooling to expand capacity and provide access to its antiviral drug Remesdesivir for COVID-19 patients across the world. "On the supply side, we are working to build a global consortium of pharmaceutical and chemical manufacturers to expand global capacity and production and have pledged to donate all our existing supply for patients in need," Gilead spokesperson told Moneycontrol in an email interview. "It will be essential for countries to work together to create enough supply for people all over the world and we look forward to these collaborative efforts. In the event of regulatory action, we are in discussions with various groups about how we might bring remdesivir to the developing world," Gilead said. Gilead didn't provide any timeframe about its launch in India. The company didn't specify if there are any Indian generic drug companies in the consortium. However, there is a possibility of Indian companies becoming part of the consortium, in the past Gilead used voluntary licenses to rope in Indian companies to manufacture and launch HIV and hepatitis-C medications in low-middle-income countries (LMICs).

India Provided 2.8 Million Anti-Malaria Drug To Other Countries: Centre
NDTV

The Ministry of External Affairs (MEA) on Thursday said that India has provided 2.8 million hydroxychloroquine (HCQ) tablets, an anti-malarial drug, deemed useful in dealing with COVID-19, and 1.9 million paracetamol tablets as part of its assistance to other countries to fight the coronavirus pandemic. India has also provided HCQ and paracetamol tablets on a commercial basis to 87 countries, said the MEA. "In terms of numbers, we have already provided 2.8 million HCQ tablets as grant assistance to 25 countries. We have also provided paracetamol, about 1.9 million tablets, in another form to 31 countries. In addition, consignments of HCQ and paracetamol are being sent to 87 countries on a commercial basis," MEA's official spokesperson Anurag Srivastava said in his opening remarks today. "These supplies are taking place both as a humanitarian aid as well as on a commercial basis," he added. In the first batch, India had listed 13 countries for the supply of hydroxychloroquine including the USA, Spain, Germany, Bahrain, Brazil, Israel, Nepal, Bhutan, Sri Lanka, Afghanistan, Maldives and Bangladesh. MEA sources, earlier this month, had told ANI that the USA had asked for 48 lakh tablets of HCQ and India has sanctioned 35.82 lakh tablets. Sources also said that Bangladesh received 20 lakh tablets of hydroxychloroquine, Nepal 10 lakh, Bhutan 2 lakh, Sri Lanka 10 lakh, Afghanistan 5 lakh, and Maldives 2 lakh.

Coronavirus - No Hospital Can Deny Treatment To COVID-19 Patients: Bengal Government
NDTV- PTI

The West Bengal government on Thursday said no approval is required by any hospital for testing an individual for COVID-19 as per the protocol of the Indian Council of Medical Research (ICMR). In an advisory, the government asked all hospitals in the state not to deny healthcare services to any patient "for any reason whatsoever". The advisory was issued a day after Chief Minister Mamata Banerjee urged private hospitals not to refuse any patient approaching them for treatment of coronavirus infection. The chief minister's appeal came after allegations were raised that some private facilities are refusing to treat patients with symptoms of coronavirus. According to the advisory, the Union Ministry of Health and Family Welfare on April 28 issued a guideline "on the early normalisation of services in the health sector for providing non-COVID 19 essential service to patients". The guideline is for the ready reference and necessary action of all hospitals and healthcare facilities in the state to ensure that such facilities are available to every patient, the advisory said. "Further it is clarified that no government approval is required for either admitting or treating any patient in any healthcare facility or for testing an individual for COVID-19 as per ICMR's testing protocol," it said. The state government has collaborated with 51 private hospitals to treat COVID-19 patients and is bearing all the expenses of their treatment, the chief minister said on Wednesday. "But other hospitals also can treat coronavirus cases by taking necessary precautionary measures. I appeal to everybody to provide treatment to them," she had said.

Smallest baby in India nursed to health and discharged from Kochi hospital
The New Indian Express

The smallest baby ever reported in India -- as tiny as a palm and weighing 350 grams when born on December 12, 2019 -- was discharged from the Lourdes Hospital here. Zaya was born as the second of twins to couple Thaneem and Zuwaina of Kodungalloor when Zuwaina was admitted with severe life-threatening pregnancy-induced hypertension during the sixth month of her pregnancy. "Due to the anticipated complications like growth retardation and reduced blood flow to the fetuses, the babies were taken out through cesarean section under the supervision of Dr Divya Jose, consultant gynecologist, and Dr Shobha Philip, head of department, anesthesiology department," a release by Lourdes Hospital said. Zoya, the first of the twins had a birth weight of 400 grams and little Zaya who was born second weighed 350 grams. "In view of several risk factors such as multiple pregnancy, growth retardation and extreme prematurity, taking care of these twins was not an easy task. Combining immature lung, brain, heart and gut were some of the hurdles faced by the treating doctors," said Dr Rojo Joy, the neonatologist of Lourdes Hospital. He said both babies had severe respiratory distress and were incubated, ventilated and admitted into NICU. "Babies were on the ventilator for 40 days till they could breathe on their own. Interventions for eye disease related to their premature birth was done by ophthalmologists from Giridhar Eye Hospital.